The Clinical Oncology Next-generation Sequencing Market is anticipated to reach US$ 449.4 Mn in value by 2022. The total market is anticipated to grow at a remarkable CAGR of 16.3% between 2022 and 2029, reaching a valuation of US$ 1.14 Bn by 2029, due to the increasing implementation of next generation sequencing (NGS) in clinical oncology for advanced individualized therapy of cancer.
Next-generation sequencing refers to the identification of the nucleotides of DNA base pairs for the diagnosis of various diseases. Oncology is one of the important applications of next-generation sequencing. It is an advanced and faster method of sequencing.ย Clinical oncology next-generation sequencingย includes kits & reagents, services, sequencing platforms, and sequencing products. The kits and reagents used for sequencing are expected to witness significant growth in the overall market.
Get a PDF Sample with Latest Market Insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-9543
North America is expected to be a prominent region in the global clinical oncology next-generation sequencing market owing to the presence of well-developed healthcare infrastructure and numerous technological advancements in the region. North America and Europe are expected to witness a significant growth rate in the clinical oncology next-generation sequencing market.
Synthesis Sequencing Technology to Hold a Major Market Value Share
Based on the technology, the clinical oncology next-generation sequencing market has been segmented into pyro sequencing, sequencing by synthesis (SBS), and Single-Molecule Real-Time Sequencing (SMRT), nanopore sequencing, ligation sequencing, and reversible dye termination sequencing. Synthesis sequencing is however expected to hold a significant share in the clinical oncology next-generation sequencing market.
Ion semiconductor sequencing is a method of DNA sequencing in which hydrogen ions are detected based on the polymerisation of DNA. Pyro-sequencing includes identifying the order of nucleotides in DNA based on the โsequencing by synthesisโ principle, in which the sequencing is performed with the help of DNA polymerase. SBS is a technique used to determine the series of base pairs in DNA, which also known as DNA is sequencing.
Ask from Market Research Expert@ https://www.futuremarketinsights.com/ask-question/rep-gb-9543
There are various applications associated with clinical oncology next-generation treatment market. They include whole tumor genome sequencing, whole tumour exome sequencing, targeted tumour genome profiling, tumour transcriptome sequencing, tumour-normal comparisons, and other applications. Targeted tumor genome profiling is expected to hold a large share of the clinical oncology next-generation treatment market.
On the basis of end user, the clinical oncology next-generation sequencing market has been segmented into hospital laboratories, clinical research organisations, diagnostic laboratories, and others. Clinical research laboratories are expected to hold a large revenue share in the clinical oncology next-generation sequencing market.
Apart from the factors driving the clinical oncology next-generation sequencing market, there are few factors that are likely to hinder the overall growth of the clinical oncology next-generation sequencing market, such as high costs associated with the establishment of sequencing platforms, low quality of outsourcing services, and inadequate availability of sequencing platforms in some regional markets.
For more Report Customization, connect with us at@ https://www.futuremarketinsights.com/customization-available/rep-gb-9543
On the other hand, increasing biomedical research using clinical oncology, increasing government funding for life science projects, substantial decline in the prices of sequencing, and technological advancements in the field of sequencing are some of the major factors driving the growth of the clinical oncology next-generation sequencing market.
Tier 1 Companies Hold Nearly 3/5th Share of Global Market Value
The report tracks some of the key companies operating in the clinical oncology next-generation sequencing market such as QIAGEN N.V., Thermo Fisher Scientific., Pacific Biosciences of California, Inc., F. Hoffmann-La Roche Ltd Oxford Nanopore Technologies, Ltd., Takara Bio, Inc., Illumina Inc., PerkinElmer Inc.and Agilent Technologies, Inc. Thermo Fischer Scientific, Oxford Nanopore Technologies Ltd., and Illumina are expected to hold a signficant share of the clinical oncology next-generation sequencing market. These first tier companies hold a share of approximately 60% in the clinical oncology next-generation sequencing market.
CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET TAXONOMY
The global clinical oncology next generation sequencing market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach in front of the reader.
๐ณ๐๐๐ ๐๐๐ ๐ ๐๐๐ ๐๐ ๐๐๐ ๐๐๐๐๐๐๐ ๐๐ ๐ ๐๐๐๐๐๐๐๐๐ ๐๐๐๐๐๐, ๐๐๐๐๐ ๐๐๐๐๐๐๐ ๐๐๐๐!
๐๐๐ช๐ฎ๐๐ฌ๐ญ ๐๐ข๐ฌ๐๐จ๐ฎ๐ง๐ญ@ https://www.futuremarketinsights.com/checkout/9543
By Product
- Sequencing Platforms
โข Sequencing Products
โข Kits and Reagents
โข Services
By Technology
- Ion Semiconductor Sequencing
โข Pyro-Sequencing
โข Synthesis Sequencing (SBS)
โข Real Time Sequencing (SMRT)
โข Ligation Sequencing
โข Reversible Dye Termination Sequencing
โข Nano-Pore Sequencing
By Application
- Whole Tumor Genome Sequencing
- Whole Tumor Exome Sequencing
- Targeted Tumor Genome Profiling
- Tumor Transcriptome Sequencing
- Tumor-normal Comparisons
- Others
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware โ 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports